MA52662A - Conjugués d'il-2 - Google Patents
Conjugués d'il-2Info
- Publication number
- MA52662A MA52662A MA052662A MA52662A MA52662A MA 52662 A MA52662 A MA 52662A MA 052662 A MA052662 A MA 052662A MA 52662 A MA52662 A MA 52662A MA 52662 A MA52662 A MA 52662A
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18164682 | 2018-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52662A true MA52662A (fr) | 2021-02-17 |
Family
ID=61832449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052662A MA52662A (fr) | 2018-03-28 | 2019-03-27 | Conjugués d'il-2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12565525B2 (fr) |
| EP (1) | EP3773680A1 (fr) |
| JP (2) | JP7490563B2 (fr) |
| KR (2) | KR20250130705A (fr) |
| CN (2) | CN111918665B (fr) |
| AU (2) | AU2019246389B2 (fr) |
| BR (1) | BR112020019639A2 (fr) |
| CA (1) | CA3093722A1 (fr) |
| IL (3) | IL308797B1 (fr) |
| MA (1) | MA52662A (fr) |
| MX (2) | MX2020009857A (fr) |
| SG (1) | SG11202007524QA (fr) |
| WO (1) | WO2019185705A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| CN111918665B (zh) | 2018-03-28 | 2024-11-26 | 阿森迪斯药物肿瘤股份有限公司 | Il-2缀合物 |
| SG11202102930YA (en) | 2018-11-08 | 2021-04-29 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| AU2020204785A1 (en) | 2019-01-04 | 2021-06-03 | Ascendis Pharma Oncology Division A/S | Sustained local drug levels for innate immune agonists |
| PH12021551591A1 (en) | 2019-01-04 | 2022-04-18 | Ascendis Pharma Oncology Div A/S | Conjugates of pattern recognition receptor agonists |
| EP3906065B1 (fr) | 2019-01-04 | 2025-04-30 | Ascendis Pharma Oncology Division A/S | Agoniste de prr et son utilisation dans le traitement du cancer |
| EP3923974A4 (fr) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| WO2020254607A1 (fr) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Composés anti-ctla4 à propriétés pd localisées |
| AU2020295725A1 (en) | 2019-06-21 | 2021-12-02 | Ascendis Pharma Oncology Division A/S | Anti-CTLA4 conjugates |
| EP4017540A1 (fr) | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Conjugués d'il-15 et leurs utilisations |
| US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| CN114437198A (zh) * | 2019-12-17 | 2022-05-06 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| PE20231648A1 (es) | 2020-04-22 | 2023-10-17 | Merck Sharp And Dohme Llc | CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO |
| KR20230019889A (ko) | 2020-06-03 | 2023-02-09 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 서열 및 이의 용도 |
| TW202219060A (zh) | 2020-08-28 | 2022-05-16 | 丹麥商阿森迪斯腫瘤製藥有限公司 | 醣基化il-2蛋白及其用途 |
| IL304365B2 (en) | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| CN1507357A (zh) | 2000-10-31 | 2004-06-23 | PRҩƷ����˾ | 提高生物活性分子传递的方法和组合物 |
| WO2003015697A2 (fr) * | 2001-08-13 | 2003-02-27 | University Of Southern California | Mutants d'interleukine-2 a toxicite reduite |
| DK1454138T3 (da) * | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| PL1620118T3 (pl) | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
| US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
| BR122019021416A2 (fr) | 2003-09-19 | 2019-12-21 | ||
| ES2367027T3 (es) * | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| CA2940803A1 (fr) * | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Lieur promedicament |
| EP2399893B1 (fr) | 2004-12-22 | 2018-08-15 | Ambrx, Inc. | Compositions contenant des acides aminés et des polypeptides non naturels, procédés les impliquant et leurs utilisations |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| JP2010533202A (ja) | 2007-07-11 | 2010-10-21 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 多置換芳香族部分を含むポリマー性薬剤送達システム |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| MX344559B (es) * | 2008-04-29 | 2016-12-20 | Ascendis Pharma As | Compuestos de hormona de crecimiento humana recombinante unidos al peg. |
| WO2009143412A2 (fr) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d’oligonucléotides |
| AU2010206840B2 (en) | 2009-01-21 | 2015-02-05 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| US20110007134A1 (en) | 2009-07-13 | 2011-01-13 | Raytheon Company | Synchronizing video images and three dimensional visualization images |
| US8331611B2 (en) | 2009-07-13 | 2012-12-11 | Raytheon Company | Overlay information over video |
| WO2011008613A1 (fr) | 2009-07-16 | 2011-01-20 | Skyhook Wireless, Inc. | Systemes et procedes pour utiliser un satellite hybride et un systeme de positionnement wlan |
| CA2769162C (fr) | 2009-07-31 | 2017-12-05 | Ascendis Pharma As | Hydrogels insolubles dans l?eau a base de polyethylene glycol biodegradable |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| CU23734A1 (es) * | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| MX337432B (es) * | 2009-12-15 | 2016-03-04 | Ascendis Pharma As | Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero. |
| EP2519228A4 (fr) | 2009-12-31 | 2013-06-19 | Enzon Pharmaceuticals Inc | Conjugués polymères de composés contenant un groupement amine aromatique comprenant un lieur d'urée libérable |
| US9561285B2 (en) * | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| EP2566334B1 (fr) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Supports solides pour la libération contrôlée de médicaments |
| ES2584381T3 (es) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
| US9221882B2 (en) | 2010-05-21 | 2015-12-29 | Technische Universitat Munchen | Biosynthetic proline/alanine random coil polypeptides and their uses |
| CN102959585B (zh) | 2010-06-30 | 2016-03-30 | 日本电气方案创新株式会社 | 属性确定方法、属性确定装置及属性确定系统 |
| WO2012065086A1 (fr) * | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugués d'une fraction il-2 et d'un polymère |
| CA2860170C (fr) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Super-agonistes et antagonistes de l'interleukine-2 |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EP2741778A1 (fr) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Promédicaments liés à des excipients polymériques hyperbranchés |
| AU2012302778B2 (en) * | 2011-08-31 | 2016-11-24 | Mie University | Vaccine preparation for cancer treatment |
| WO2013036857A1 (fr) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Coupleurs au sulfone |
| WO2014028748A1 (fr) | 2012-08-15 | 2014-02-20 | Irm Llc | Anticorps d'interleukine 2 et complexes d'anticorps |
| WO2014056923A1 (fr) | 2012-10-11 | 2014-04-17 | Ascendis Pharma Ophthalmology Division A/S | Pro-médicaments de neutralisation de vegf pour le traitement d'états oculaires |
| CA2883833C (fr) | 2012-10-11 | 2020-10-27 | Ascendis Pharma A/S | Promedicaments sous forme d'hydrogel |
| WO2014060512A1 (fr) | 2012-10-17 | 2014-04-24 | Novo Nordisk Health Care Ag | Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance |
| WO2014100014A1 (fr) | 2012-12-17 | 2014-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Super-complexes 2 avec anticorps pour une amélioration de la thérapie par il-2 |
| CN105722860A (zh) * | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| KR102410090B1 (ko) * | 2014-02-21 | 2022-06-16 | 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 | 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 |
| US11633487B2 (en) | 2014-08-06 | 2023-04-25 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| WO2016025647A1 (fr) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Traitement tumoral synergique avec l'il-2, un anticorps thérapeutique, et un vaccin contre le cancer |
| SG11201703870UA (en) * | 2014-11-18 | 2017-06-29 | Ascendis Pharma Endocrinology Div As | Novel polymeric hgh prodrugs |
| CA3007976C (fr) * | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Promedicaments du cnp possedant de grands fragments a role de transporteur |
| MY208384A (en) | 2016-03-01 | 2025-05-05 | Ascendis Pharma Bone Diseases As | Pth prodrugs |
| US12453778B2 (en) * | 2016-09-29 | 2025-10-28 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release PTH compounds |
| CU24483B1 (es) | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| AR111190A1 (es) | 2017-03-22 | 2019-06-12 | Genentech Inc | Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados |
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| JP7404252B2 (ja) | 2017-11-08 | 2023-12-25 | ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド | 生体分子のコンジュゲートおよびその使用 |
| US12280118B2 (en) | 2017-12-27 | 2025-04-22 | Kyowa Kirin Co., Ltd. | IL-2 variant |
| CN111918665B (zh) | 2018-03-28 | 2024-11-26 | 阿森迪斯药物肿瘤股份有限公司 | Il-2缀合物 |
| AU2019246390B2 (en) * | 2018-03-28 | 2025-03-27 | Ascendis Pharma A/S | Conjugates |
| MX2021000801A (es) | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
| CA3098930A1 (fr) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Nouvelle interleukine 2 et utilisation associee |
| US20220227837A1 (en) | 2019-05-24 | 2022-07-21 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
| WO2020254607A1 (fr) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Composés anti-ctla4 à propriétés pd localisées |
| CN114437198A (zh) | 2019-12-17 | 2022-05-06 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| KR20230019889A (ko) | 2020-06-03 | 2023-02-09 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 서열 및 이의 용도 |
| TW202219060A (zh) | 2020-08-28 | 2022-05-16 | 丹麥商阿森迪斯腫瘤製藥有限公司 | 醣基化il-2蛋白及其用途 |
-
2019
- 2019-03-27 CN CN201980022172.XA patent/CN111918665B/zh active Active
- 2019-03-27 AU AU2019246389A patent/AU2019246389B2/en active Active
- 2019-03-27 CN CN202411614476.4A patent/CN119504973A/zh active Pending
- 2019-03-27 IL IL308797A patent/IL308797B1/en unknown
- 2019-03-27 MA MA052662A patent/MA52662A/fr unknown
- 2019-03-27 IL IL324874A patent/IL324874A/en unknown
- 2019-03-27 JP JP2020552812A patent/JP7490563B2/ja active Active
- 2019-03-27 SG SG11202007524QA patent/SG11202007524QA/en unknown
- 2019-03-27 KR KR1020257027619A patent/KR20250130705A/ko active Pending
- 2019-03-27 CA CA3093722A patent/CA3093722A1/fr active Pending
- 2019-03-27 MX MX2020009857A patent/MX2020009857A/es unknown
- 2019-03-27 IL IL277572A patent/IL277572B2/en unknown
- 2019-03-27 US US17/042,610 patent/US12565525B2/en active Active
- 2019-03-27 BR BR112020019639-8A patent/BR112020019639A2/pt unknown
- 2019-03-27 EP EP19713040.4A patent/EP3773680A1/fr active Pending
- 2019-03-27 WO PCT/EP2019/057709 patent/WO2019185705A1/fr not_active Ceased
- 2019-03-27 KR KR1020207031136A patent/KR102950463B1/ko active Active
-
2020
- 2020-09-22 MX MX2025007999A patent/MX2025007999A/es unknown
-
2024
- 2024-02-22 JP JP2024025984A patent/JP2024073467A/ja active Pending
- 2024-11-05 AU AU2024259730A patent/AU2024259730A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025007999A (es) | 2025-08-01 |
| JP2024073467A (ja) | 2024-05-29 |
| US12565525B2 (en) | 2026-03-03 |
| KR102950463B1 (ko) | 2026-04-09 |
| WO2019185705A1 (fr) | 2019-10-03 |
| KR20200139730A (ko) | 2020-12-14 |
| CN119504973A (zh) | 2025-02-25 |
| IL324874A (en) | 2026-01-01 |
| KR20250130705A (ko) | 2025-09-02 |
| RU2020135268A (ru) | 2022-04-28 |
| MX2020009857A (es) | 2021-01-08 |
| SG11202007524QA (en) | 2020-09-29 |
| CA3093722A1 (fr) | 2019-10-03 |
| CN111918665B (zh) | 2024-11-26 |
| AU2024259730A1 (en) | 2024-12-05 |
| EP3773680A1 (fr) | 2021-02-17 |
| AU2019246389B2 (en) | 2024-08-22 |
| IL277572B1 (en) | 2024-01-01 |
| US20210024602A1 (en) | 2021-01-28 |
| IL308797A (en) | 2024-01-01 |
| AU2019246389A1 (en) | 2020-08-27 |
| IL308797B1 (en) | 2026-01-01 |
| IL277572A (en) | 2020-11-30 |
| JP2021519336A (ja) | 2021-08-10 |
| CN111918665A (zh) | 2020-11-10 |
| IL277572B2 (en) | 2024-05-01 |
| JP7490563B2 (ja) | 2024-05-27 |
| BR112020019639A2 (pt) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52662A (fr) | Conjugués d'il-2 | |
| IL286291A (en) | Compounds and conjugates thereof | |
| EP3735685A4 (fr) | Panneau d'affichage | |
| EP3807644A4 (fr) | Conjugués anticorps-oligonucléotide | |
| DK3794042T5 (da) | Anti-muc1-exatecet-antistof-lægemiddelkonjugat | |
| EP3750149C0 (fr) | Panneau d'affichage | |
| EP3793613C0 (fr) | Immunoconjugués | |
| EP4023666A4 (fr) | Dérivé d'interleukine-2 | |
| EP3798719A4 (fr) | Panneau d'affichage | |
| IL291486A (en) | Therapeutic conjugates | |
| IL284007A (en) | Rifamycin analogs and antibody-drug conjugates thereof | |
| EP3532240A4 (fr) | Base d'outillage | |
| SI3927315T1 (sl) | Okusne formulacije | |
| IL292766A (en) | Antibody-drug conjugates targeting claudin 18.2 | |
| EP4030778A4 (fr) | Casque d'écoute | |
| MA51157A (fr) | Récepteurs de l'interleukine darique | |
| EP3864058A4 (fr) | Composition photodurcissable | |
| EP3790683A4 (fr) | Ensemble d'entraînement | |
| EP3762456A4 (fr) | Composition de dispersant d'asphaltène | |
| EP3773574A4 (fr) | Formulations d'amlodipine | |
| EP3761922C0 (fr) | Support d'épaule orthétique | |
| IL279855A (en) | Improvements in immunogenic conjugates | |
| DK3911298T3 (da) | Formuleringer | |
| EP3851070A4 (fr) | Structure d'implant | |
| EP3792601A4 (fr) | Détecteur d'angle |